64244-87-7Relevant articles and documents
Structure-Activity Relationship of Phenylpyrazolones against Trypanosoma cruzi
Sijm, Maarten,Sterk, Geert Jan,Caljon, Guy,Maes, Louis,de Esch, Iwan J. P.,Leurs, Rob
supporting information, p. 1310 - 1321 (2020/05/08)
Chagas disease is a neglected parasitic disease caused by the parasitic protozoan Trypanosoma cruzi and currently affects around 8 million people. Previously, 2-isopropyl-5-(4-methoxy-3-(pyridin-3-yl)phenyl)-4,4-dimethyl-2,4-dihydro-3H-pyrazol-3-one (NPD-0227) was discovered to be a sub-micromolar inhibitor (pIC50=6.4) of T. cruzi. So far, SAR investigations of this scaffold have focused on the alkoxy substituent, the pyrazolone nitrogen substituent and the aromatic substituent of the core phenylpyrazolone. In this study, modifications of the phenyldihydropyrazolone scaffold are described. Variations were introduced by installing different substituents on the phenyl core, modifying the geminal dimethyl and installing various bio-isosteres of the dihydropyrazolone group. The anti T. cruzi activity of NPD-0227 could not be surpassed as the most potent compounds show pIC50 values of around 6.3. However, valuable additional SAR data for this interesting scaffold was obtained, and the data suggest that a scaffold hop is feasible as the pyrazolone moiety can be replaced by a oxazole or oxadiazole with minimal loss of activity.
Novel malonamide derivatives as αvβ3 antagonists. Syntheses and evaluation of 3-(3-indolin-1-yl-3-oxopropanoyl)aminopropanoic acids on vitronectin interaction with αvβ3
Nagashima,Akamatsu,Kawaminami,Kawazoe,Ogami,Matsumoto,Okada,Suzuki,Tsukamoto
, p. 1420 - 1432 (2007/10/03)
In attempt to find novel integrin of αvβ3 antagonists, we selected SC65811 and its guanidine analogue (1) as lead compounds. Modification of the glycine part of SC65811 led to a new series of malonamide derivatives that exhibited αvβ3 inhibitory activity. Among them, (R,S)-3-{3-[6-(3-benzylureido)indolin-1-yl]-3-oxopropanoylamino}-3- (pyridin-3-yl)propanoic acid (43a) showed not only potent activity with an IC50 value of 3.0 nM but also good selectivity for αvβ3 relative to αIIbβ3, α5β1, and αvβ5 with IC50 values of 19000, 11000, and 14 nM, respectively. Furthermore, optimization of 43a led to the most potent αvβ3 antagonist, (R,S)-3-(3-{6-[(4,5-dihydro-1H-imidazol-2-yl)aminoindolin-1-yl}- 3-oxopropanoylamino)-3-(quinolin-3-yl)propanoic acid (431) with an IC50 value of 0.42 nM. The synthesis and the structure-activity relationships of these malonamide derivatives are presented.
α-substituted malonester amides: Tools to define the relationship between ACAT inhibition and adrenal toxicity
Sliskovic, Drago R.,Picard, Joseph A.,O'Brien, Patrick M.,Liao, Peggy,Howard Roark,Roth, Bruce D.,Anderson, Maureen A.,Mueller, Sandra Bak,Bocan, Thomas M.A.,Bousley, Richard F.,Hamelehle, Katherine L.,Homan, Reynold,Reindel, James F.,Stanfield, Richard L.,Turluck, Daniel,Krause, Brian R.
, p. 682 - 690 (2007/10/03)
We prepared a series of α-substituted malonester amides that were evaluated for their ability to inhibit acyl-CoA:cholesterol O-acyl transferase activity in vitro and to lower plasma total cholesterol levels in a variety of cholesterol-fed animal models.